Login to Your Account



Clinic Roundup


Tuesday, September 10, 2013
Astellas Pharma Inc., of Tokyo, said in liver transplant patients, initiating Advagraf prolonged-release capsules (tacrolimus) therapy immediately post-transplant, at a dose 25 percent lower than the upper recommended limit, in combination with basiliximab, resulted in significantly better renal function and a lower incidence of acute organ rejection when compared with standard dose Advagraf therapy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription